ABIVAX SA (ABVX)
Automate Your Wheel Strategy on ABVX
With Tiblio's Option Bot, you can configure your own wheel strategy including ABVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABVX
- Rev/Share 0.0854
- Book/Share 0.6424
- PB 8.0878
- Debt/Equity 2.6912
- CurrentRatio 1.8157
- ROIC -0.558
- MktCap 329596452.1215
- FreeCF/Share -1.2245
- PFCF -4.2608
- PE -3.7248
- Debt/Assets 0.5322
- DivYield 0
- ROE -1.055
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ABVX | Morgan Stanley | -- | Equal Weight | -- | $12 | March 20, 2025 |
| Initiation | ABVX | JMP Securities | -- | Mkt Outperform | -- | $33 | Dec. 4, 2024 |
News
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
Published: June 02, 2025 by: Schwab Network
Sentiment: Positive
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Read More
Abivax publishes financial reports with the French and U.S. securities regulatory agencies
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on March …
Read More
Abivax Announces Full Year 2024 Financial Results
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Abivax Announces Full Year 2024 Financial Results • Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025 Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025 PARIS, France – March 24, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, announced today its full-year financial results, …
Read More
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High?
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 360.5% upside potential for Abivax SA Sponsored ADR (ABVX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax's Pivotal ABTECT Phase 3 Trial PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m.
Read More
About ABIVAX SA (ABVX)
- IPO Date 2023-10-20
- Website https://www.abivax.com
- Industry Biotechnology
- CEO Mr. Marc M. P. de Garidel M.B.A.
- Employees 69